ES2681839T3 - Un procedimiento para diagnosticar cirrosis biliar primaria (CBP) usando nuevos autoantígenos - Google Patents
Un procedimiento para diagnosticar cirrosis biliar primaria (CBP) usando nuevos autoantígenos Download PDFInfo
- Publication number
- ES2681839T3 ES2681839T3 ES15194007.9T ES15194007T ES2681839T3 ES 2681839 T3 ES2681839 T3 ES 2681839T3 ES 15194007 T ES15194007 T ES 15194007T ES 2681839 T3 ES2681839 T3 ES 2681839T3
- Authority
- ES
- Spain
- Prior art keywords
- elisa
- cbp
- patients
- serum
- sera
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US248768P | 2000-11-16 | ||
US24876809P | 2009-10-05 | 2009-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2681839T3 true ES2681839T3 (es) | 2018-09-17 |
Family
ID=43857083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15194007.9T Active ES2681839T3 (es) | 2009-10-05 | 2010-10-05 | Un procedimiento para diagnosticar cirrosis biliar primaria (CBP) usando nuevos autoantígenos |
ES10822527.7T Active ES2566762T3 (es) | 2009-10-05 | 2010-10-05 | Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10822527.7T Active ES2566762T3 (es) | 2009-10-05 | 2010-10-05 | Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos |
Country Status (7)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2965189C (en) * | 2009-10-05 | 2020-06-30 | Ambergen, Inc. | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens |
CN102627695B (zh) * | 2012-03-23 | 2014-10-22 | 中国医学科学院北京协和医院 | 原发性胆汁性肝硬化特异性自身抗原及其应用 |
CN104292323B (zh) * | 2012-03-23 | 2017-04-05 | 中国医学科学院北京协和医院 | 原发性胆汁性肝硬化特异性自身抗原及其应用 |
CN104292322A (zh) * | 2012-03-23 | 2015-01-21 | 中国医学科学院北京协和医院 | 原发性胆汁性肝硬化特异性自身抗原及其应用 |
US20220196662A1 (en) * | 2019-03-15 | 2022-06-23 | Chan Zuckerberg Biohub, Inc. | Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer |
WO2022150536A1 (en) * | 2021-01-08 | 2022-07-14 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing primary biliary cirrhosis |
CN113009148A (zh) * | 2021-02-10 | 2021-06-22 | 中国医学科学院北京协和医院 | 用于诊断抗sp100抗体阳性与阴性pbc患者的糖链标志物及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
CA1341231C (en) | 1986-12-16 | 2001-05-15 | Ross Leon Coppel | Primary biliary cirrhosis autoantigen |
JPH03291568A (ja) * | 1990-04-09 | 1991-12-20 | Igaku Seibutsugaku Kenkyusho:Kk | 抗ミトコンドリアm↓2抗体の検出用試薬及び測定法 |
JP3472048B2 (ja) * | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
CA2256684A1 (en) * | 1996-06-24 | 1997-12-31 | Patrick Leung | Recombinant fusion protein comprising pdc-e2, bcoadc-e2, and ogdc-e2 and uses thereof |
JPH1138008A (ja) * | 1997-07-16 | 1999-02-12 | Sumitomo Electric Ind Ltd | 自己抗体の検出方法および検出試薬 |
WO2002008383A2 (en) * | 2000-07-24 | 2002-01-31 | The General Hospital Corporation | Sp110, a polypeptide component of the nuclear body |
AU2002254431A1 (en) * | 2001-03-27 | 2002-10-08 | M. Eric Gershwin | Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them |
NZ548532A (en) * | 2004-01-21 | 2009-09-25 | Gilead Sciences Inc | Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis |
JP2006071409A (ja) * | 2004-09-01 | 2006-03-16 | Kansai Tlo Kk | シェーグレン症候群診断キット |
WO2007043103A1 (ja) * | 2005-09-30 | 2007-04-19 | Kansai Technology Licensing Organization Co., Ltd. | シェーグレン症候群診断法及び診断キット |
JP2007245505A (ja) | 2006-03-15 | 2007-09-27 | Fujifilm Corp | 平版印刷版原版、平版印刷版およびその作製方法 |
US20090047689A1 (en) * | 2007-06-20 | 2009-02-19 | John Kolman | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma |
JP5471724B2 (ja) | 2009-09-30 | 2014-04-16 | 大日本印刷株式会社 | 化粧シート |
CA2965189C (en) * | 2009-10-05 | 2020-06-30 | Ambergen, Inc. | A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens |
JP2012206482A (ja) | 2011-03-30 | 2012-10-25 | Daikyonishikawa Corp | 樹脂成形品の組付け構造 |
-
2010
- 2010-10-05 CA CA2965189A patent/CA2965189C/en active Active
- 2010-10-05 ES ES15194007.9T patent/ES2681839T3/es active Active
- 2010-10-05 EP EP15194007.9A patent/EP3012631B1/en active Active
- 2010-10-05 US US13/500,411 patent/US8852956B2/en active Active
- 2010-10-05 EP EP10822527.7A patent/EP2486407B1/en active Active
- 2010-10-05 WO PCT/US2010/051475 patent/WO2011044125A1/en active Application Filing
- 2010-10-05 ES ES10822527.7T patent/ES2566762T3/es active Active
- 2010-10-05 AU AU2010303628A patent/AU2010303628B2/en active Active
- 2010-10-05 JP JP2012532147A patent/JP5710623B2/ja active Active
- 2010-10-05 CA CA2776688A patent/CA2776688C/en active Active
-
2014
- 2014-06-27 US US14/318,498 patent/US20150057170A1/en not_active Abandoned
-
2015
- 2015-03-04 JP JP2015041977A patent/JP6012794B2/ja active Active
- 2015-10-07 AU AU2015238816A patent/AU2015238816B2/en active Active
-
2017
- 2017-03-24 US US15/469,350 patent/US11885802B2/en active Active
-
2023
- 2023-11-28 US US18/522,114 patent/US20240159749A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP5710623B2 (ja) | 2015-04-30 |
US20240159749A1 (en) | 2024-05-16 |
WO2011044125A8 (en) | 2012-09-13 |
US8852956B2 (en) | 2014-10-07 |
AU2015238816B2 (en) | 2017-10-05 |
US20170307607A1 (en) | 2017-10-26 |
EP3012631B1 (en) | 2018-05-23 |
JP6012794B2 (ja) | 2016-10-25 |
JP2013506837A (ja) | 2013-02-28 |
US20120244562A1 (en) | 2012-09-27 |
WO2011044125A1 (en) | 2011-04-14 |
CA2965189C (en) | 2020-06-30 |
CA2776688C (en) | 2017-06-20 |
EP2486407A4 (en) | 2013-04-10 |
EP2486407A1 (en) | 2012-08-15 |
CA2965189A1 (en) | 2011-04-14 |
AU2010303628A1 (en) | 2012-04-12 |
AU2010303628B2 (en) | 2015-07-09 |
EP2486407B1 (en) | 2016-02-10 |
AU2015238816A1 (en) | 2015-10-29 |
CA2776688A1 (en) | 2011-04-14 |
US11885802B2 (en) | 2024-01-30 |
ES2566762T3 (es) | 2016-04-15 |
US20150057170A1 (en) | 2015-02-26 |
JP2015143695A (ja) | 2015-08-06 |
EP3012631A1 (en) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240159749A1 (en) | Method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens | |
Amlani et al. | Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis | |
EP2729810B1 (en) | Myositis | |
DK2406633T3 (en) | COMPOSITIONS AND PROCEDURES FOR CHARACTERIZING ARTHRITIC CONDITIONS | |
US11609237B2 (en) | Marker sequences for diagnosing and stratifying systemic sclerosis patients | |
US20180059107A1 (en) | Method of detecting or diagnosing sjogren's syndrome based on the presence of auto-antibody against aquaporin 5 | |
Kaga et al. | Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA | |
EP3701264A1 (en) | Method and means for diagnosing autoimmune hepatitis using autoantibody markers | |
JPWO2011099435A1 (ja) | Ku86とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法 | |
WO2019075109A1 (en) | BIOMARKERS IN AUTOIMMUNE HEPATIC DISEASE | |
CN109725156B (zh) | 多肽sle2018-v002在诊断系统性红斑狼疮试剂盒中的应用 | |
US10690668B2 (en) | Method for detecting polyomavirus reactivation | |
JP5605375B2 (ja) | Ku86に対する自己抗体の免疫測定方法、それに用いるキット、及びそれを用いた原発性肝細胞癌の判定方法 | |
Sasai et al. | Anti-aminoacyl tRNA synthetase antibodies showing the discrepancy between enzyme-linked immunosorbent assay and RNA-immunoprecipitation | |
Kuwana | Immunodiagnosis of Scleroderma |